<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157962</url>
  </required_header>
  <id_info>
    <org_study_id>EA1/207/09</org_study_id>
    <nct_id>NCT01157962</nct_id>
  </id_info>
  <brief_title>Sentinel Concept in Early Stage Cervical Cancer</brief_title>
  <official_title>Prospective, Randomized and Multicentre Study for Investigation of Valence of Sentinel Lymph Nodes Concept in Patients With Cervical Cancer ≤ 2 cm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of present study is to inspect, if the removal alone of sentinel lymph nodes in women&#xD;
      with early Cervix Carcinoma lead to, at equal length, overall survival like entire systematic&#xD;
      dissection of lymph node and at the same time is accompanied with a considerably reduction of&#xD;
      associated intra and post operative complications of lymph node dissection.&#xD;
&#xD;
      For this purpose were randomized about 1200 patients with histological assured cervix&#xD;
      carcinoma in stages FIGO 1a1 L1 V0, FIGO 1a2 L0 or L1 V0, FIGO1b1 L0 or L1 V0= 2 cm&#xD;
      randomization. In the branch A takes place exclusively dissection sentinel lymph node, in the&#xD;
      branch B takes place entire pelvic lymph node dissection. Afterwards takes place in tumor&#xD;
      free lymph nodes the removal of uterus by a radical hysterectomy or, in presence of the wish&#xD;
      of children, radical trachelectomy. In affected tumoural lymph nodes takes place systematic&#xD;
      pelvic and peri aortic lymph node dissection followed by primary Radiochemotherapy.&#xD;
&#xD;
      Primary end point is overall survival; this for both groups must be equal. Secondary end&#xD;
      point is peri- and postoperative morbidity inclusive quality of life, the benefits for women&#xD;
      must be evident with sentinel- lymph node dissection, don't have to show for both groups any&#xD;
      significant difference.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After randomization and assignment to experimental or control group lymphadenectomy is&#xD;
      carried out.&#xD;
&#xD;
      Four different techniques can be used: 1) laparoscopic transperitoneal 2) laparoscopic&#xD;
      retroperitoneal 3) open extraperitoneal 4) open transperitoneal. Radioactive labeling of&#xD;
      sentinel-lymph nodes with 99technetium-marked colloid and/or patent blue is carried out. On&#xD;
      the day prior to the operation 50mBq 99technetium or on the day of operation 10 mBq&#xD;
      99technetium is injected subepithelially in the cervix at 12, 3, 6 and 9 o'clock.&#xD;
      Preoperatively 4 cc patent blue are injected in the same manner subepithelially. At the&#xD;
      beginning of surgery parametrial tumor involvement, intrabdominal tumor dissemination,&#xD;
      invasion of vesica-cervical and recto-vaginal septum are excluded. A lavage of cul-de-sac for&#xD;
      cytological analysis is performed. The retroperitoneum is opened lateral of iliac vessels and&#xD;
      blue colored lymph or radioactive nodes are removed. Sentinel- lymph node's radioactive&#xD;
      signal is documented in counts per second (cps).&#xD;
&#xD;
      If no sentinel-lymph node is detected, complete pelvic lymph node dissection is carried out.&#xD;
      If tumor involved pelvic lymph nodes are shown, paraaortic lymph node dissection is carried&#xD;
      out. If sentinel- or pelvic lymph nodes are quoted as tumor free at frozen sections, radical&#xD;
      hysterectomy or radical trachelectomy is performed. Radical hysterectomy follows in an&#xD;
      extension a type-2 variation. In patients with positive lymph nodes in frozen section or in&#xD;
      definitive histo-pathology primary chemoradiation is performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
    <description>Primary study end point is that overall survival of patients with sentinel-concept, has not to differentiate from that one of patients with systematic lymph node dissection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morbidity</measure>
    <time_frame>one year</time_frame>
    <description>Secondary study end points are peri- und postoperative complications percentage and life quality after EORTC QLQ C-30 and local control. Local control percentage must exhibit no difference for both groups. Complications percentage and life quality must be significative better in branch with sentinel-lymph node dissection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Group A Sentinel lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In group A exclusively sentinel lymphadenectomy is performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B radical pelvine lymphadenectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in group B radical systematic pelvic lymphadenectomy is done. In patients with tumor free lymph nodes either radical hysterectomy or, in women seeking parenthood, radical trachelectomy is performed. If lymph nodes are tumor-involved systematic pelvic and paraaortic lymphadenectomy followed by primary chemoradiation is recommended.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphadenectomy in cervical cancer</intervention_name>
    <description>Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy</description>
    <arm_group_label>Group A Sentinel lymphadenectomy</arm_group_label>
    <arm_group_label>Group B radical pelvine lymphadenectomy</arm_group_label>
    <other_name>Sentinel node dissection and radical pelvic dissection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Karnofsky index&#xD;
&#xD;
          -  Patients aged 18-70&#xD;
&#xD;
          -  Histological assured cervix cancer (Squamous epithelium- or Adenoids cancer,&#xD;
             adenosquamous cancer)&#xD;
&#xD;
          -  Stadium FIGO from 1a1 L1 V0, FIGO 1a2 L0 or L1 V0, till FIGO 1b1 L0 or L1 V0 ≤ 2cm&#xD;
&#xD;
          -  Completed and signed consent form&#xD;
&#xD;
          -  Cooperation qualities of patients&#xD;
&#xD;
          -  Performed explanation patients and written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumour thickness &gt; 2cm, FIGO- staging &gt; 1b1&#xD;
&#xD;
          -  Neuroendocrine tumoural or mixed types with neuroendocrine tissues&#xD;
&#xD;
          -  Tumoural invasion in vascular system (V1)&#xD;
&#xD;
          -  Pregnancy, during lactation women without reliable contraception during&#xD;
             radiochemotherapy&#xD;
&#xD;
          -  Existing malignant diseases (Exception: basalioma of the skin)&#xD;
&#xD;
          -  Radiotherapy of pelvis in anamnesis&#xD;
&#xD;
          -  Severe internal associated diseases (Myocardial infarction, Heart pathology, Heart&#xD;
             insufficiency NYHA III/IV, Severe chronic obstructive bronchopulmonary disease, kidney&#xD;
             insufficiency, diabetes mellitus poorly regulated, uncontrolled infections)&#xD;
             Anaesthesia not allowed&#xD;
&#xD;
          -  Psychiatric diseases, which put off participating and after care&#xD;
&#xD;
          -  HIV infection, or rather AIDS disease&#xD;
&#xD;
          -  Drug addicted&#xD;
&#xD;
          -  Precedent motorial or sensorial Polyneuropathies&gt;CTC grade 1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charite University of Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achim Schneider, Professor</last_name>
      <phone>+49 30 450 564 172</phone>
      <email>achim.schneider@charite.de</email>
    </contact>
    <investigator>
      <last_name>Achim Schneider, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Altgassen C, Hertel H, Brandstädt A, Köhler C, Dürst M, Schneider A; AGO Study Group. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol. 2008 Jun 20;26(18):2943-51. doi: 10.1200/JCO.2007.13.8933.</citation>
    <PMID>18565880</PMID>
  </results_reference>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Campus Mitte/ Campus Benjamin Franklin Charité university</name_title>
    <organization>Gynecological Oncology Ward</organization>
  </responsible_party>
  <keyword>Sentinel Concept</keyword>
  <keyword>Lymphadenectomy</keyword>
  <keyword>Early Stage Cervical Cancer</keyword>
  <keyword>Overall Survive</keyword>
  <keyword>Improvement Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

